| Date Filed | Type | Description |
| 08/14/2023 |
4
| CROCKER GARY L (See Remarks) has filed a Form 4 on MERRIMACK PHARMACEUTICALS INC|
Txns:
| Bought 2,000 shares
@ $12.5196, valued at
$25k
Bought 2,000 shares
@ $12.4326, valued at
$24.9k
|
|
| 08/14/2023 |
SC 13D/A
| Western Standard LLC reports a 13.9% stake in Merrimack Pharmaceuticals, Inc. |
| 08/09/2023 |
4
| Andersen Eric (Director) has filed a Form 4 on MERRIMACK PHARMACEUTICALS INC|
Txns:
| Bought 84,636 shares
@ $12.0037, valued at
$1M
Bought 49,857 shares
@ $12.0037, valued at
$598.5k
Bought 68,431 shares
@ $11.9959, valued at
$820.9k
Bought 18,626 shares
@ $11.9959, valued at
$223.4k
|
|
| 08/03/2023 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits Interactive Data |
| 08/03/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 06/08/2023 |
4
| Radeljevic Ana (Director) has filed a Form 4 on MERRIMACK PHARMACEUTICALS INC|
Txns:
| Granted 7,000 options to buy
@ $12.48, valued at
$87.4k
|
|
| 06/08/2023 |
4
| Nielsen Ulrik B. (Director) has filed a Form 4 on MERRIMACK PHARMACEUTICALS INC|
Txns:
| Granted 7,000 options to buy
@ $12.48, valued at
$87.4k
|
|
| 06/08/2023 |
4
| CROCKER GARY L (See Remarks) has filed a Form 4 on MERRIMACK PHARMACEUTICALS INC|
Txns:
| Granted 8,000 options to buy
@ $12.48, valued at
$99.8k
|
|
| 06/07/2023 |
8-K
| Submission of Matters to a Vote of Security Holders Interactive Data |
| 05/04/2023 |
8-K
| Quarterly results |
| 05/04/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
| 04/21/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 04/21/2023 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 03/22/2023 |
4
| Andersen Eric (Director) has filed a Form 4 on MERRIMACK PHARMACEUTICALS INC|
Txns:
| Bought 127,409 shares
@ $11.52, valued at
$1.5M
Bought 33,181 shares
@ $11.52, valued at
$382.2k
|
|
| 03/09/2023 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits Interactive Data |
| 03/09/2023 |
10-K
| Annual Report for the period ended December 31, 2022 |
| 03/01/2023 |
4/A
| Andersen Eric (Director) has filed a Form 4 on MERRIMACK PHARMACEUTICALS INC|
Txns:
| Bought 19,750 shares
@ $11.3576, valued at
$224.3k
Bought 4,985 shares
@ $11.3576, valued at
$56.6k
Bought 1,782 shares
@ $11.3998, valued at
$20.3k
Bought 450 shares
@ $11.3998, valued at
$5.1k
|
|
| 02/14/2023 |
SC 13G/A
| Point72 Asset Management, L.P. reports a 0% stake in Merrimack Pharmaceuticals, Inc. |
| 02/13/2023 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 02/01/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 01/31/2023 |
4
| Andersen Eric (Director) has filed a Form 4 on MERRIMACK PHARMACEUTICALS INC|
Txns:
| Bought 17,465 shares
@ $11.3965, valued at
$199k
Bought 4,410 shares
@ $11.3965, valued at
$50.3k
|
|
| 01/17/2023 |
4
| Levy Noah G. (Director) has filed a Form 4 on MERRIMACK PHARMACEUTICALS INC|
Txns:
| Bought 100,000 shares
@ $11.9, valued at
$1.2M
|
|
| 01/09/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 01/04/2023 |
4
| Levy Noah G. (Director) has filed a Form 4 on MERRIMACK PHARMACEUTICALS INC|
Txns:
| Bought 1,300 shares
@ $11.2423, valued at
$14.6k
Bought 5,300 shares
@ $11.2384, valued at
$59.6k
|
|
| 01/04/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 01/03/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 12/05/2022 |
8-K
| Quarterly results |
| 11/30/2022 |
S-8
| Form S-8 - Securities to be offered to employees in employee benefit plans: |
| 11/09/2022 |
8-K
| Quarterly results |
| 11/03/2022 |
8-K
| Quarterly results |
| 11/03/2022 |
10-Q
| Quarterly Report for the period ended September 30, 2022 |
| 08/04/2022 |
8-K
| Quarterly results |
| 08/04/2022 |
10-Q
| Quarterly Report for the period ended June 30, 2022 |
| 08/04/2022 |
SC 13G
| Point72 Asset Management, L.P. reports a 6.7% stake in Merrimack Pharmaceuticals, Inc. |
|